within Pharmacolibrary.Drugs.ATC.M;

model M05BA08
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 6.166666666666667e-05,
    adminDuration  = 600,
    adminMass      = 4 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0065,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0027,
    k12             = 0.66,
    k21             = 0.66
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>M05BA08</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Zoledronic acid is a third-generation bisphosphonate used primarily for the treatment of osteoporosis, Paget’s disease of bone, and to prevent skeletal-related events in patients with cancers such as multiple myeloma and bone metastases from solid tumors. It is approved and widely used clinically for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters derived from adult cancer patients (solid tumors, multiple myeloma) receiving single intravenous doses.</p><h4>References</h4><ol><li><p>Tanaka, S (2016). [Pharmacokinetics of Zoledronic acid[once-yearly bisphosphonate(intravenous infusion)].]. <i>Clinical calcium</i> 26(11) 1605–1613. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27777393/\">https://pubmed.ncbi.nlm.nih.gov/27777393</a></p></li><li><p>Deeks, ED, &amp; Perry, CM (2008). Zoledronic acid: a review of its use in the treatment of osteoporosis. <i>Drugs &amp; aging</i> 25(11) 963–986. DOI:<a href=\"https://doi.org/10.2165/0002512-200825110-00007\">10.2165/0002512-200825110-00007</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18947264/\">https://pubmed.ncbi.nlm.nih.gov/18947264</a></p></li><li><p>Chen, T, et al., &amp; Skerjanec, A (2002). Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. <i>Journal of clinical pharmacology</i> 42(11) 1228–1236. DOI:<a href=\"https://doi.org/10.1177/009127002762491316\">10.1177/009127002762491316</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12412821/\">https://pubmed.ncbi.nlm.nih.gov/12412821</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end M05BA08;
